{"nctId":"NCT01598987","briefTitle":"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.","startDateStruct":{"date":"2012-10"},"conditions":["Renal Function","Liver Transplant"],"count":56,"armGroups":[{"label":"Everolimus based regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation."]}],"interventions":[{"name":"Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nSigned informed consent from both parents or legal guardian(s) prior to patient participation in the study.\n\nPaediatric liver transplant recipients aged greater than or equal to 1 month and younger than 18 years of age.\n\nPaediatric recipients at the earliest 1 month and latest 6 month after liver transplantation.\n\nKey Exclusion Criteria:\n\nPatients with hepato-biliary malignancies and/or patients transplanted due to fulminant hepatitis /acute liver failure.\n\nPresence of thrombosis of any major hepatic arteries, major/reconstructed hepatic veins, portal vein or inferior vena cava at any time prior to the start of study drug.\n\nPatients with serum creatinine value \\>2 times age-related ULN at Baseline or who received renal replacement therapy within one week prior to the start of study drug and patients with a confirmed spot urine protein/creatinine ratio indicating a urinary protein excretion \\>500 mg/m2/24 hrs, at Baseline.\n\nPatients with clinically significant systemic infection and/or in a critical care setting requiring life support measures such as mechanical ventilation, dialysis, or vasopressor agents.\n\nPatients with a known hypersensitivity to the drugs used on study or their class, or to any of the excipients.\n\nPregnant or nursing (lactating) female patients, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Î²HCG laboratory test (\\>9 mIU/mL) at Baseline.\n\nFemale patients of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they agree for abstinence from sexual activity.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Month","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate - Month 12","description":"Evolution of renal function assessed by estimated Glomerular Filtration Rate (eGFR) calculated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula (Schwartz 2009), expressed in mean change in eGFR of CKiD between start of study (baseline assessment) and Month 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"19.52"}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimates for Failure Rates of Efficacy Endpoints","description":"The proportion of patients with composite efficacy failure (treated biopsy proven acute rejection\\[tBPAR\\], graft loss \\[GL\\] , death \\[D\\]) before/at Month 12 and Month 24, estimated with Kaplan-Meier (KM) methods and the proportion of patients who experienced any of the components of composite efficacy failure (tBPAR, GL, D) before/at Month 12 and Month 24, separately for each component.\n\nAR: acute rejection; BPAR: biopsy proven acute rejection. Rate = Kaplan-Meier estimate for failure in %; CI = confidence interval for failure rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate - Month 24","description":"Evolution of renal function assessed by estimated Glomerular Filtration Rate (eGFR) calculated by the Chronic Kidney Disease in Children (CKiD) Schwartz formula (Schwartz 2009), expressed in mean change in eGFR of CKiD between start of study (baseline assessment) and Month 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"19.55"}]}]}]},{"type":"SECONDARY","title":"Growth Development - Height at Baseline and Month 12","description":"Individual growth measurements were compared with the gender and age-specific growth percentiles in the CDC growth charts for the US population. Each value observed is thus represented by the (approximated) percentage of subjects with a lower value in the reference population. Changes were calculated on this scale and thus express the change in growth measurements relative to the percentiles in the CDC growth charts.\n\nPatients were classified into growth percentile categories (\\<=5, \\>5-25, \\>25-50, \\>50-75, \\>75-95 and \\>95% percentile).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"26.7","spread":null},{"groupId":"OG002","value":"16.7","spread":null},{"groupId":"OG003","value":"14.3","spread":null},{"groupId":"OG004","value":"25.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"28.6","spread":null},{"groupId":"OG004","value":"50.0","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"44.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"25.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"16.7","spread":null},{"groupId":"OG003","value":"14.3","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"26.7","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"42.9","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Development - Weight at Baseline and Month 12","description":"Individual growth measurements were compared with the gender and age-specific growth percentiles in the CDC growth charts for the US population. Each value observed is thus represented by the (approximated) percentage of subjects with a lower value in the reference population. Changes were calculated on this scale and thus express the change in growth measurements relative to the percentiles in the CDC growth charts.\n\nPatients were classified into growth percentile categories (\\<=5, \\>5-25, \\>25-50, \\>50-75, \\>75-95 and \\>95% percentile).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"42.9","spread":null},{"groupId":"OG003","value":"72.7","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"28.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"18.2","spread":null},{"groupId":"OG004","value":"33.3","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"9.1","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"57.1","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"33.3","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"36.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Development - Weight at Baseline and Month 24","description":"Individual growth measurements were compared with the gender and age-specific growth percentiles in the CDC growth charts for the US population. Each value observed is thus represented by the (approximated) percentage of subjects with a lower value in the reference population. Changes were calculated on this scale and thus express the change in growth measurements relative to the percentiles in the CDC growth charts.\n\nPatients were classified into growth percentile categories (\\<=5, \\>5-25, \\>25-50, \\>50-75, \\>75-95 and \\>95% percentile).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"12.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"25.0","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"12.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"12.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"13.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"37.5","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Growth Development - Height at Baseline and Month 24","description":"Individual growth measurements were compared with the gender and age-specific growth percentiles in the CDC growth charts for the US population. Each value observed is thus represented by the (approximated) percentage of subjects with a lower value in the reference population. Changes were calculated on this scale and thus express the change in growth measurements relative to the percentiles in the CDC growth charts.\n\nPatients were classified into growth percentile categories (\\<=5, \\>5-25, \\>25-50, \\>50-75, \\>75-95 and \\>95% percentile).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"9.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"50.0","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"27.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"50.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"40.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":56},"commonTop":["Diarrhoea","Pyrexia","Vomiting","Nasopharyngitis","Upper respiratory tract infection"]}}}